US OKs Refocus' presbyopia implant trials:
This article was originally published in Clinica
The US FDA has given Refocus the go-head to start phase II trials of its implant system for treating presbyopia (long-sightedness). The Dallas, Texas firm plans to test its scleral spacing procedure in 100 patients at 10 sites across the US.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.